SCHEMBL2025934

SCHEMBL2025934

COc1cc(O[Si](C)(C)C(C)(C)C)ccc1B(O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 6/20 0.42
CA12 O43570 5/20 0.42
CA9 Q16790 5/20 0.42
ENPP2 Q13822 2/20 0.41
TUBB4A P04350 4/20 0.37
TUBB P07437 4/20 0.37
TUBA3C P0DPH7 4/20 0.37
TUBA1B P68363 4/20 0.37
TUBA4A P68366 4/20 0.37
TUBB4B P68371 4/20 0.37
TUBB3 Q13509 4/20 0.37
TUBB2A Q13885 4/20 0.37
TUBB8 Q3ZCM7 4/20 0.37
TUBA3E Q6PEY2 4/20 0.37
TUBA1A Q71U36 4/20 0.37
TUBA1C Q9BQE3 4/20 0.37
TUBB6 Q9BUF5 4/20 0.37
TUBB2B Q9BVA1 4/20 0.37
TUBB1 Q9H4B7 4/20 0.37
PREP P48147 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29951251 1.00 CA1 (0.42) CA1CA12CA9ENPP2TUBB4A
SCHEMBL29953678 0.88 TUBB4A (0.43) CA1CA12CA9ENPP2TUBB4A
SCHEMBL1612747 0.81 CA12 (0.35) CA1CA12CA9ENPP2PREP
SCHEMBL2022605 0.81 CA12 (0.44) CA1CA12CA9PREPHSP90AA1
SCHEMBL14511843 0.80 PREP (0.40) CA1CA12CA9ENPP2TUBB4A
SCHEMBL2114690 0.79 CA12 (0.43) CA1CA12CA9PREPHSP90AA1
SCHEMBL29951222 0.79 CA12 (0.43) CA1CA12CA9PREPHSP90AA1
SCHEMBL2023774 0.79 CA12 (0.45) CA1CA12CA9PREPCA2
SCHEMBL16135178 0.78 TUBB4A (0.49) CA1CA12CA9TUBB4ATUBB
SCHEMBL12577662 0.78 CA12 (0.44) CA1CA12CA9PREPHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968552-B2 Oxadiazolidinedione compound ASTELLAS PHARMA INC. (JP) 2011-06-28 US disclosed
US-7968552-B2 Oxadiazolidinedione compound ASTELLAS PHARMA INC. (JP) 2011-06-28 US disclosed
US-20090186909-A1 Oxadiazolidinedione Compound ASTELLAS PHARMA INC. (JP) 2009-07-23 US disclosed
US-20090186909-A1 Oxadiazolidinedione Compound ASTELLAS PHARMA INC. (JP) 2009-07-23 US disclosed
EP-2011788-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2009-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186909-A1 Oxadiazolidinedione Compound GPR119, GPR39, GPR65 CA1 4091/4885CA12 4396/4885CA9 3645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.